Published in Immunology on June 01, 2014
Ontogeny and polarization of macrophages in inflammation: blood monocytes versus tissue macrophages. Front Immunol (2015) 1.05
The ubiquitin proteasome system in glia and its role in neurodegenerative diseases. Front Mol Neurosci (2014) 0.96
Replication and transcription on a collision course: eukaryotic regulation mechanisms and implications for DNA stability. Front Genet (2015) 0.90
Dual destructive and protective roles of adaptive immunity in neurodegenerative disorders. Transl Neurodegener (2014) 0.86
Eryptosis as a marker of Parkinson's disease. Aging (Albany NY) (2014) 0.86
The role of the immune system in triplet repeat expansion diseases. Mediators Inflamm (2015) 0.85
Joint genetic analysis of hippocampal size in mouse and human identifies a novel gene linked to neurodegenerative disease. BMC Genomics (2014) 0.83
Activation of Alpha 7 Cholinergic Nicotinic Receptors Reduce Blood-Brain Barrier Permeability following Experimental Traumatic Brain Injury. J Neurosci (2016) 0.83
Alternative source of stem cells derived from human periodontal ligament: a new treatment for experimental autoimmune encephalomyelitis. Stem Cell Res Ther (2016) 0.82
Neurodegeneration severity can be predicted from early microglia alterations monitored in vivo in a mouse model of chronic glaucoma. Dis Model Mech (2015) 0.82
Neutralization of TNFSF10 ameliorates functional outcome in a murine model of Alzheimer's disease. Brain (2014) 0.81
EP2-PKA signaling is suppressed by triptolide in lipopolysaccharide-induced microglia activation. J Neuroinflammation (2015) 0.81
The Mechanobiology of Aging. Annu Rev Biomed Eng (2015) 0.81
MCP-1 and CCR2 gene polymorphisms in Parkinson's disease in a Han Chinese cohort. Neurol Sci (2014) 0.80
LPS-induced Murine Neuroinflammation Model: Main Features and Suitability for Pre-clinical Assessment of Nutraceuticals. Curr Neuropharmacol (2016) 0.80
Role for cFMS in maintaining alternative macrophage polarization in SIV infection: implications for HIV neuropathogenesis. J Neuroinflammation (2015) 0.79
Elevated C-Reactive Protein Is Associated with Cognitive Decline in Outpatients of a General Hospital: The Project in Sado for Total Health (PROST). Dement Geriatr Cogn Dis Extra (2016) 0.78
Induction of heat shock proteins in differentiated human neuronal cells following co-application of celastrol and arimoclomol. Cell Stress Chaperones (2016) 0.78
Blood and CSF biomarkers in brain subcortical ischemic vascular disease: Involved pathways and clinical applicability. J Cereb Blood Flow Metab (2016) 0.78
Pleiotrophin regulates microglia-mediated neuroinflammation. J Neuroinflammation (2017) 0.78
Resveratrol Treatment after Status Epilepticus Restrains Neurodegeneration and Abnormal Neurogenesis with Suppression of Oxidative Stress and Inflammation. Sci Rep (2015) 0.77
Leukemia inhibitor factor promotes functional recovery and oligodendrocyte survival in rat models of focal ischemia. Eur J Neurosci (2014) 0.76
Induction of the type I interferon response in neurological forms of Gaucher disease. J Neuroinflammation (2016) 0.76
An Effective Method to Identify Shared Pathways and Common Factors among Neurodegenerative Diseases. PLoS One (2015) 0.76
Reduced β-amyloid pathology in an APP transgenic mouse model of Alzheimer's disease lacking functional B and T cells. Acta Neuropathol Commun (2015) 0.76
Cellular Interactions and Signaling in neuroAIDS: Emerging Issues Colloquium. J Neuroimmune Pharmacol (2014) 0.76
Age-dependent neuroinflammation and cognitive decline in a novel Ala152Thr-Tau transgenic mouse model of PSP and AD. Acta Neuropathol Commun (2016) 0.76
Neuroinflammatory paradigms in lysosomal storage diseases. Front Neurosci (2015) 0.76
Regnase-1 in microglia negatively regulates high mobility group box 1-mediated inflammation and neuronal injury. Sci Rep (2016) 0.76
Glial Modulation by N-acylethanolamides in Brain Injury and Neurodegeneration. Front Aging Neurosci (2016) 0.75
An Overview of the Protective Effects of Chitosan and Acetylated Chitosan Oligosaccharides against Neuronal Disorders. Mar Drugs (2017) 0.75
A double-blind, rct testing beneficial modulation of BDNF in middle-aged, life style-stressed subjects: a clue to brain protection? J Clin Diagn Res (2014) 0.75
Recent Advances in Nanoparticle-Mediated Delivery of Anti-Inflammatory Phytocompounds. Int J Mol Sci (2017) 0.75
Neuroinflammation, neurodegeneration and regeneration in multiple sclerosis: intercorrelated manifestations of the immune response. Neural Regen Res (2016) 0.75
Systemic Administration of Induced Neural Stem Cells Regulates Complement Activation in Mouse Closed Head Injury Models. Sci Rep (2017) 0.75
Balancing the immune response in the brain: IL-10 and its regulation. J Neuroinflammation (2016) 0.75
Disparate Changes in Plasma and Brainstem Cytokine Levels in Adult and Ageing Rats Associated with Age-Related Changes in Facial Motor Neuron Number, Snout Muscle Morphology, and Exploratory Behavior. Front Neurol (2016) 0.75
Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy. Parkinsons Dis (2016) 0.75
The role of indoleamine 2,3-dioxygenase-aryl hydrocarbon receptor pathway in the TLR4-induced tolerogenic phenotype in human DCs. Sci Rep (2017) 0.75
Histological Architecture Underlying Brain-Immune Cell-Cell Interactions and the Cerebral Response to Systemic Inflammation. Front Immunol (2017) 0.75
Cyclooxygenase-1 as a Potential Therapeutic Target for Seizure Suppression: Evidences from Zebrafish Pentylenetetrazole-Seizure Model. Front Neurol (2016) 0.75
Immune response in peripheral axons delays disease progression in SOD1(G93A) mice. J Neuroinflammation (2016) 0.75
Commentary: Immunochemical Markers of the Amyloid Cascade in the Hippocampus in Motor Neuron Diseases. Front Neurol (2017) 0.75
Redox Imbalance and Viral Infections in Neurodegenerative Diseases. Oxid Med Cell Longev (2016) 0.75
A roadmap for investigating the role of the prion protein in depression associated with neurodegenerative disease. Prion (2016) 0.75
Synaptoimmunology - roles in health and disease. Mol Brain (2017) 0.75
Age-related macular degeneration and mortality: the Melbourne Collaborative Cohort Study. Eye (Lond) (2017) 0.75
Expression and Differential Responsiveness of Central Nervous System Glial Cell Populations to the Acute Phase Protein Serum Amyloid A. Sci Rep (2017) 0.75
TLDc proteins: new players in the oxidative stress response and neurological disease. Mamm Genome (2017) 0.75
The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature (2011) 6.71
Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat Neurosci (2011) 4.21
Alzheimer's disease beta-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci U S A (2006) 3.98
M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat Neurosci (2013) 3.59
Inflammation in neurodegenerative diseases. Immunology (2010) 3.22
Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat Neurosci (2007) 3.02
Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med (2012) 2.90
IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat Immunol (2012) 2.62
Neurotransmitter-triggered transfer of exosomes mediates oligodendrocyte-neuron communication. PLoS Biol (2013) 2.61
Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry (2012) 2.21
The immunology of acute stroke. Nat Rev Neurol (2012) 2.06
Alzheimer's disease and infection: do infectious agents contribute to progression of Alzheimer's disease? Alzheimers Dement (2009) 1.89
Comparison of polarization properties of human adult microglia and blood-derived macrophages. Glia (2012) 1.73
Toll-like receptor 3 on adult human astrocytes triggers production of neuroprotective mediators. Glia (2006) 1.72
Newly described pattern recognition receptors team up against intracellular pathogens. Nat Rev Immunol (2013) 1.69
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain (2003) 1.62
Cross-talk between neural stem cells and immune cells: the key to better brain repair? Nat Neurosci (2012) 1.55
Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis. Brain (2013) 1.53
Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurol (2013) 1.52
How do immune cells support and shape the brain in health, disease, and aging? J Neurosci (2013) 1.51
Pro-cognitive properties of T cells. Nat Rev Immunol (2012) 1.50
Contribution of systemic inflammation to chronic neurodegeneration. Acta Neuropathol (2010) 1.45
Classic and new animal models of Parkinson's disease. J Biomed Biotechnol (2012) 1.45
Alzheimer's disease - a neurospirochetosis. Analysis of the evidence following Koch's and Hill's criteria. J Neuroinflammation (2011) 1.41
Preclinical stroke research--advantages and disadvantages of the most common rodent models of focal ischaemia. Br J Pharmacol (2011) 1.39
T-cells in Alzheimer's disease. Neuromolecular Med (2005) 1.38
Neuronal expression of CD22: novel mechanism for inhibiting microglial proinflammatory cytokine production. Glia (2004) 1.37
New perspectives on central and peripheral immune responses to acute traumatic brain injury. J Neuroinflammation (2012) 1.34
Inflammation in ALS and SMA: sorting out the good from the evil. Neurobiol Dis (2009) 1.29
Features of microglia and neuroinflammation relevant to environmental exposure and neurotoxicity. Int J Environ Res Public Health (2011) 1.27
Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst Rev (2012) 1.26
Factors regulating microglia activation. Front Cell Neurosci (2013) 1.26
Importance of T lymphocytes in brain injury, immunodeficiency, and recovery after cerebral ischemia. J Cereb Blood Flow Metab (2012) 1.22
Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.22
Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. J Neuroinflammation (2013) 1.21
Microglia, Alzheimer's disease, and complement. Int J Alzheimers Dis (2012) 1.21
In vitro and in vivo models of multiple sclerosis. CNS Neurol Disord Drug Targets (2012) 1.20
Don't fence me in: harnessing the beneficial roles of astrocytes for spinal cord repair. Restor Neurol Neurosci (2008) 1.19
C1q induction and global complement pathway activation do not contribute to ALS toxicity in mutant SOD1 mice. Proc Natl Acad Sci U S A (2013) 1.17
Preactive lesions in multiple sclerosis. Curr Opin Neurol (2009) 1.16
Viruses and multiple sclerosis. CNS Neurol Disord Drug Targets (2012) 1.15
Primary oligodendrocyte death does not elicit anti-CNS immunity. Nat Neurosci (2012) 1.15
Psychostimulant abuse and neuroinflammation: emerging evidence of their interconnection. Neurotox Res (2012) 1.14
Review: contribution of transgenic models to understanding human prion disease. Neuropathol Appl Neurobiol (2010) 1.11
Complement activation in the injured central nervous system: another dual-edged sword? J Neuroinflammation (2012) 1.11
High mobility group box protein-1 promotes cerebral edema after traumatic brain injury via activation of toll-like receptor 4. Glia (2013) 1.10
Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain (2009) 1.09
The janus head of T cell aging - autoimmunity and immunodeficiency. Front Immunol (2013) 1.09
Alphab-crystallin is a target for adaptive immune responses and a trigger of innate responses in preactive multiple sclerosis lesions. J Neuropathol Exp Neurol (2010) 1.07
Neuronal CCL21 up-regulates microglia P2X4 expression and initiates neuropathic pain development. EMBO J (2011) 1.06
iPSC-derived neural precursors exert a neuroprotective role in immune-mediated demyelination via the secretion of LIF. Nat Commun (2013) 1.06
Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. Brain (2012) 1.06
Phenotyping primary human microglia: tight regulation of LPS responsiveness. Glia (2012) 1.06
Cognitive impairment and cortical degeneration in neuromyelitis optica. Ann Neurol (2013) 1.05
Evidence of parallels between mercury intoxication and the brain pathology in autism. Acta Neurobiol Exp (Wars) (2012) 1.04
The role of the immune system in Huntington's disease. Clin Dev Immunol (2013) 1.03
Shedded neuronal ICAM-5 suppresses T-cell activation. Blood (2008) 1.03
Infectious agents and neurodegeneration. Mol Neurobiol (2012) 1.03
Axonal loss and gray matter pathology as a direct result of autoimmunity to neurofilaments. Neurobiol Dis (2008) 1.02
Innate and adaptive immunity in amyotrophic lateral sclerosis: evidence of complement activation. Neurobiol Dis (2011) 1.01
Stress proteins in oligodendrocytes: differential effects of heat shock and oxidative stress. J Neurochem (2001) 1.00
Neuron-directed autoimmunity in the central nervous system: entities, mechanisms, diagnostic clues, and therapeutic options. Curr Opin Neurol (2012) 1.00
Mast cells, glia and neuroinflammation: partners in crime? Immunology (2014) 0.99
Biozzi mice: of mice and human neurological diseases. J Neuroimmunol (2005) 0.99
Th17 cell-mediated neuroinflammation is involved in neurodegeneration of aβ1-42-induced Alzheimer's disease model rats. PLoS One (2013) 0.98
The Brain's Aging Immune System. Aging Dis (2010) 0.98
Multiplexed RNA trafficking in oligodendrocytes and neurons. Biochim Biophys Acta (2008) 0.98
T cells specifically targeted to amyloid plaques enhance plaque clearance in a mouse model of Alzheimer's disease. PLoS One (2010) 0.96
An update of animal models of Alzheimer disease with a reevaluation of plaque depositions. Exp Neurobiol (2013) 0.95
Deficiency of the complement regulator CD59a exacerbates Wallerian degeneration. Mol Immunol (2009) 0.94
Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias. J Alzheimers Dis (2011) 0.94
Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PLoS One (2013) 0.94
Retroviruses and amyotrophic lateral sclerosis. Antiviral Res (2013) 0.94
Activation and control of CNS innate immune responses in health and diseases: a balancing act finely tuned by neuroimmune regulators (NIReg). CNS Neurol Disord Drug Targets (2011) 0.93
Oligodendrocyte-microglia cross-talk in the central nervous system. Immunology (2014) 0.93
The wobbler mouse, an ALS animal model. Mol Genet Genomics (2013) 0.92
HIV-1 infection and neurocognitive impairment in the current era. Rev Med Virol (2011) 0.90
Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2013) 0.90
Immunology of neuromyelitis optica: a T cell-B cell collaboration. Ann N Y Acad Sci (2013) 0.89
Mucopolysaccharide diseases: a complex interplay between neuroinflammation, microglial activation and adaptive immunity. J Inherit Metab Dis (2013) 0.89
Chaperone-like activity of high-mobility group box 1 protein and its role in reducing the formation of polyglutamine aggregates. J Immunol (2013) 0.89
Astrocytic therapies for neuronal repair in stroke. Neurosci Lett (2013) 0.88
Mechanisms in the development of multiple sclerosis lesions: reconciling autoimmune and neurodegenerative factors. CNS Neurol Disord Drug Targets (2012) 0.88
Senescence-accelerated Mice (SAMs) as a Model for Brain Aging and Immunosenescence. Aging Dis (2011) 0.88
Subventricular zone neural progenitors protect striatal neurons from glutamatergic excitotoxicity. Brain (2012) 0.88
Prion disease and the innate immune system. Viruses (2012) 0.86
Impact of minocycline on neurodegenerative diseases in rodents: a meta-analysis. Rev Neurosci (2013) 0.86
Alpha-B-crystallin induces an immune-regulatory and antiviral microglial response in preactive multiple sclerosis lesions. J Neuropathol Exp Neurol (2013) 0.85
Mouse models of polyglutamine diseases: review and data table. Part I. Mol Neurobiol (2012) 0.84
Presence of reactive microglia and neuroinflammatory mediators in a case of frontotemporal dementia with P301S mutation. Neurodegener Dis (2011) 0.84
Potential control of multiple sclerosis by cannabis and the endocannabinoid system. CNS Neurol Disord Drug Targets (2012) 0.84
Adenosine A(2A) Receptor Antagonists and Parkinson's Disease. ACS Chem Neurosci (2011) 0.84
HSV, axonal transport and Alzheimer's disease: in vitro and in vivo evidence for causal relationships. Future Virol (2012) 0.83
Neuronal influence behind the central nervous system regulation of the immune cells. Front Integr Neurosci (2013) 0.83
Plexin-A4 is expressed in oligodendrocyte precursor cells and acts as a mediator of semaphorin signals. Biochem Biophys Res Commun (2006) 0.82
Sweet and sour--oxidative and carbonyl stress in neurological disorders. CNS Neurol Disord Drug Targets (2011) 0.82
Alterations in gene expression in Caenorhabditis elegans associated with organophosphate pesticide intoxication and recovery. BMC Genomics (2013) 0.81
Substantia nigra depigmentation and exposure to encephalitis lethargica. Ann Neurol (2012) 0.81
Interleukin-17A increases neurite outgrowth from adult postganglionic sympathetic neurons. J Neurosci (2012) 0.80
Design of a novel globular protein fold with atomic-level accuracy. Science (2003) 13.06
Protein structure prediction using Rosetta. Methods Enzymol (2004) 12.05
Predicting protein structures with a multiplayer online game. Nature (2010) 9.95
Toward high-resolution de novo structure prediction for small proteins. Science (2005) 9.18
Protein-protein docking with simultaneous optimization of rigid-body displacement and side-chain conformations. J Mol Biol (2003) 8.35
Macromolecular modeling with rosetta. Annu Rev Biochem (2008) 8.32
Kemp elimination catalysts by computational enzyme design. Nature (2008) 8.19
Evaluation of structural and evolutionary contributions to deleterious mutation prediction. J Mol Biol (2002) 7.79
High-resolution structure prediction and the crystallographic phase problem. Nature (2007) 7.67
De novo computational design of retro-aldol enzymes. Science (2008) 7.62
Protein structure prediction and analysis using the Robetta server. Nucleic Acids Res (2004) 7.39
ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol (2011) 7.33
Consistent blind protein structure generation from NMR chemical shift data. Proc Natl Acad Sci U S A (2008) 6.76
A simple physical model for binding energy hot spots in protein-protein complexes. Proc Natl Acad Sci U S A (2002) 6.18
Crystal structure of a monomeric retroviral protease solved by protein folding game players. Nat Struct Mol Biol (2011) 5.02
Towards robust regional estimates of CO2 sources and sinks using atmospheric transport models. Nature (2002) 4.71
An orientation-dependent hydrogen bonding potential improves prediction of specificity and structure for proteins and protein-protein complexes. J Mol Biol (2003) 4.63
Assigning function to yeast proteins by integration of technologies. Mol Cell (2003) 4.58
Ca2+ indicators based on computationally redesigned calmodulin-peptide pairs. Chem Biol (2006) 4.52
Computational design of proteins targeting the conserved stem region of influenza hemagglutinin. Science (2011) 4.42
Protein-protein docking with backbone flexibility. J Mol Biol (2007) 4.32
Computational design of an enzyme catalyst for a stereoselective bimolecular Diels-Alder reaction. Science (2010) 4.32
Improving physical realism, stereochemistry, and side-chain accuracy in homology modeling: Four approaches that performed well in CASP8. Proteins (2009) 4.27
Computational redesign of endonuclease DNA binding and cleavage specificity. Nature (2006) 4.06
Quantitative reactivity profiling predicts functional cysteines in proteomes. Nature (2010) 4.04
Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination. Nature (2007) 3.92
Automated de novo prediction of native-like RNA tertiary structures. Proc Natl Acad Sci U S A (2007) 3.87
Algorithm discovery by protein folding game players. Proc Natl Acad Sci U S A (2011) 3.74
Computational redesign of protein-protein interaction specificity. Nat Struct Mol Biol (2004) 3.66
Modeling structurally variable regions in homologous proteins with rosetta. Proteins (2004) 3.64
Structure prediction for CASP8 with all-atom refinement using Rosetta. Proteins (2009) 3.64
ROSETTALIGAND: protein-small molecule docking with full side-chain flexibility. Proteins (2006) 3.60
Rational HIV immunogen design to target specific germline B cell receptors. Science (2013) 3.55
Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol (2002) 3.53
High-resolution mapping of protein sequence-function relationships. Nat Methods (2010) 3.47
Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature (2006) 3.45
Computational alanine scanning of protein-protein interfaces. Sci STKE (2004) 3.41
Automated prediction of CASP-5 structures using the Robetta server. Proteins (2003) 3.41
New algorithms and an in silico benchmark for computational enzyme design. Protein Sci (2006) 3.40
Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis (2009) 3.32
Inflammation in neurodegenerative diseases. Immunology (2010) 3.22
An engineered microbial platform for direct biofuel production from brown macroalgae. Science (2012) 3.20
A large scale test of computational protein design: folding and stability of nine completely redesigned globular proteins. J Mol Biol (2003) 3.08
Atomic accuracy in predicting and designing noncanonical RNA structure. Nat Methods (2010) 3.07
Progress in modeling of protein structures and interactions. Science (2005) 3.05
Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A (2009) 3.01
Structure prediction for CASP7 targets using extensive all-atom refinement with Rosetta@home. Proteins (2007) 3.01
NMR structure determination for larger proteins using backbone-only data. Science (2010) 3.00
Refinement of protein structures into low-resolution density maps using rosetta. J Mol Biol (2009) 2.94
The 3D profile method for identifying fibril-forming segments of proteins. Proc Natl Acad Sci U S A (2006) 2.88
De novo prediction of three-dimensional structures for major protein families. J Mol Biol (2002) 2.88
RosettaLigand docking with full ligand and receptor flexibility. J Mol Biol (2008) 2.86
Voltage sensor conformations in the open and closed states in ROSETTA structural models of K(+) channels. Proc Natl Acad Sci U S A (2006) 2.81
Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol (2003) 2.80
Multipass membrane protein structure prediction using Rosetta. Proteins (2006) 2.79
Computational thermostabilization of an enzyme. Science (2005) 2.79
Rosetta predictions in CASP5: successes, failures, and prospects for complete automation. Proteins (2003) 2.77
Improved molecular replacement by density- and energy-guided protein structure optimization. Nature (2011) 2.74
Improved side-chain modeling for protein-protein docking. Protein Sci (2005) 2.72
Close agreement between the orientation dependence of hydrogen bonds observed in protein structures and quantum mechanical calculations. Proc Natl Acad Sci U S A (2004) 2.71
Elicitation of structure-specific antibodies by epitope scaffolds. Proc Natl Acad Sci U S A (2010) 2.68
Role of conformational sampling in computing mutation-induced changes in protein structure and stability. Proteins (2010) 2.56
CASD-NMR: critical assessment of automated structure determination by NMR. Nat Methods (2009) 2.50
A vast repertoire of Dscam binding specificities arises from modular interactions of variable Ig domains. Cell (2007) 2.50
Principles for designing ideal protein structures. Nature (2012) 2.50
Solution structure of a minor and transiently formed state of a T4 lysozyme mutant. Nature (2011) 2.49
Physically realistic homology models built with ROSETTA can be more accurate than their templates. Proc Natl Acad Sci U S A (2006) 2.47
Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation. Nature (2011) 2.46
Protein-DNA binding specificity predictions with structural models. Nucleic Acids Res (2005) 2.45
De novo protein structure generation from incomplete chemical shift assignments. J Biomol NMR (2008) 2.43
No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet (2004) 2.43
Assessing the utility of coevolution-based residue-residue contact predictions in a sequence- and structure-rich era. Proc Natl Acad Sci U S A (2013) 2.43
Computational design of protein-protein interactions. Curr Opin Chem Biol (2004) 2.39
Contact order revisited: influence of protein size on the folding rate. Protein Sci (2003) 2.37
Prediction of the structure of symmetrical protein assemblies. Proc Natl Acad Sci U S A (2007) 2.35
Computational design of self-assembling protein nanomaterials with atomic level accuracy. Science (2012) 2.33
Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol (2008) 2.29
Progress and challenges in high-resolution refinement of protein structure models. Proteins (2005) 2.28
Design, activity, and structure of a highly specific artificial endonuclease. Mol Cell (2002) 2.25
RosettaScripts: a scripting language interface to the Rosetta macromolecular modeling suite. PLoS One (2011) 2.21
A synthetic homing endonuclease-based gene drive system in the human malaria mosquito. Nature (2011) 2.20
Increased Diels-Alderase activity through backbone remodeling guided by Foldit players. Nat Biotechnol (2012) 2.19
Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. Science (2011) 2.17
Optimization of affinity, specificity and function of designed influenza inhibitors using deep sequencing. Nat Biotechnol (2012) 2.14
A randomised cross-over trial investigating the ease of use and preference of two dry powder inhalers in patients with asthma or chronic obstructive pulmonary disease. Expert Opin Drug Deliv (2013) 2.13
De novo determination of protein backbone structure from residual dipolar couplings using Rosetta. J Am Chem Soc (2002) 2.12
Dissecting the genome of the polyploid crop oilseed rape by transcriptome sequencing. Nat Biotechnol (2011) 2.12
Free modeling with Rosetta in CASP6. Proteins (2005) 2.10
Improved beta-protein structure prediction by multilevel optimization of nonlocal strand pairings and local backbone conformation. Proteins (2006) 2.07
Structural basis for scaffolding-mediated assembly and maturation of a dsDNA virus. Proc Natl Acad Sci U S A (2011) 2.03
Atomic model of the type III secretion system needle. Nature (2012) 2.02
A conserved structural motif mediates formation of the periplasmic rings in the type III secretion system. Nat Struct Mol Biol (2009) 2.02
Crystal structure of the HSV-1 Fc receptor bound to Fc reveals a mechanism for antibody bipolar bridging. PLoS Biol (2006) 1.99
High-resolution comparative modeling with RosettaCM. Structure (2013) 1.96
RosettaHoles: rapid assessment of protein core packing for structure prediction, refinement, design, and validation. Protein Sci (2009) 1.96
Homology modeling using parametric alignment ensemble generation with consensus and energy-based model selection. Nucleic Acids Res (2006) 1.96
An improved protein decoy set for testing energy functions for protein structure prediction. Proteins (2003) 1.94
Prediction of CASP6 structures using automated Robetta protocols. Proteins (2005) 1.94
Computational design of a new hydrogen bond network and at least a 300-fold specificity switch at a protein-protein interface. J Mol Biol (2006) 1.93